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Extracellular vesicles (EVs) are the collective term for the various vesicles that are released by cells into the
extracellular space. Such vesicles include exosomes and microvesicles, which vary by their size and/or protein
and genetic cargo. With the discovery that EVs contain genetic material in the form of RNA (evRNA) has
come the increased interest in these vesicles for their potential use as sources of disease biomarkers and
potential therapeutic agents. Rapid developments in the availability of deep sequencing technologies have
enabled the study of EV-related RNA in detail. In October 2012, the International Society for Extracellular
Vesicles (ISEV) held a workshop on ‘‘evRNA analysis and bioinformatics.’’ Here, we report the conclusions
of one of the roundtable discussions where we discussed evRNA analysis technologies and provide some
guidelines to researchers in the field to consider when performing such analysis.
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E
xtracellular vesicles (EVs) include exosomes and
microvesicles that are released by many cell types
into the extracellular space. Research in this field
has increased dramatically over the last decade due
to increased recognition of the role of EVs in cellular
processes underlying homeostasis and disease patho-
biology, and their potential use as biomarkers and
therapeutic agents. A key discovery was that EVs contain
RNA, allowing a role for these vesicles in the inter-
cellular transfer of genetically encoded messages. The
RNA types initially discovered in EVs were messenger
RNA (mRNA) and microRNA (miRNA) (1,2). Currently,
there is an increasing interest in analysing the complete
transcriptome of EVs, and so far only a limited number
of RNA deep sequencing based characterization of
transcriptomes of different EV types have been published
(36). With the rapid advances in deep sequencing or
Next Generation Sequencing (NGS) techniques, large
numbers of unexpected non-coding RNA species have
been discovered in cellular transcriptomes (7). These
transcripts were found to overlap with exons, introns, and
intergenic regions, (8) and several of the newly discovered
non-coding RNAs have been implicated in regulation
of transcription or translation. Interestingly, EVs were
found to be enriched in several types of such non-coding
RNA species (36). Currently, the mechanism(s) respon-
sible for extracellular vesicle RNA (evRNA) trafficking
and release, in addition to the function of this RNA
identified in a heterogeneous pool of EVs, remains un-
clear. Since most of the transcriptome undergoes exten-
sive post-transcriptional modification, this may also
add to the complexity of evRNA. Given the additional
complexities concerning the nomenclature of EVs, isola-
tion methods, variety of platforms for deep sequencing
and downstream bioinformatics analysis, the topic of
‘‘evRNA analysis and bioinformatics’’ was discussed at
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the International Society of Extracellular Vesicles (ISEV)
Research Seminar held in New York in October 2012.
Here, we present a summary of the roundtable discussion
of this topic and present points of consideration and
awareness to researchers working in the area of evRNA
analysis, in addition to defining the challenges associated
with this area of research. This position paper should
be read in conjunction with the recent publication by
Witwer et al. in this journal (9) that covers the discus-
sion on sample collection, vesicle isolation, and analysis
methods in EV research.
Source of material for evRNA analysis
Vesicles can be isolated from a number of sources
including cell culture supernatants and biological fluids,
such as plasma, serum, urine, milk, and cerebrospinal
fluid. Different methods may be required for effective
isolation of EVs from these different sources (9). With
regard to parameters influencing evRNA analysis, we
discuss below some of the key issues for EVs isolated
from cell culture supernatants and bodily fluids.
Cell culture supernatants
Many studies utilize cell culture supernatants as a source
of EVs for analysis. We considered several experimental
variables that should be reported when presenting analysis
of evRNA. Reporting the confluency and viability of the
cells using commercially available reagents would allow
assessment of the culture health prior to evRNA analysis.
Apoptotic or necrotic cells in cell cultures can release
RNA-containing apoptotic bodies or nucleoprotein
complexes, which contaminate the evRNA population.
Ideally, a control experiment is to induce apoptosis in a
culture and prepare EVs (10), comparing their properties
with those of the experimental sample. Furthermore, as
many culture systems can be contaminated with myco-
plasma, a statement as to whether the cultures used in the
analysis were checked for the presence of these contami-
nants should be provided.
The method used to isolate the EVs should be provided
in as much detail as possible, allowing exact replication of
the approach. Descriptions should include the number of
cells cultured, volumes of media, centrifugation para-
meters (including rotor and tube type, centrifugal force,
time), and the downstream storage conditions prior to
RNA extraction. Fractionation of pelleted vesicles using
density gradient media (such as sucrose or iodixanol) is
recommended to isolate intact vesicles separated from
contaminants.
With regard to the culturing conditions, it is important
to detail whether vesicle-containing supplements, such
as foetal calf serum (FCS) were added to the culture
medium and how EVs were depleted from these additives
before use. Furthermore, characterization of the isolated
vesicles should be performed to demonstrate the presence
of vesicles and provide an assessment of their purity.
Techniques such as transmission electron microscopy
(TEM) (11), nanoparticle tracking analysis (NTA; Nano-
sight) (12) and tunable resistive pulse sensing (qTRS;
qNano) (13) can be employed to provide analysis of the
approximate size of vesicles present in the preparation.
Additionally, flow cytometry, NTA, qNano, and dynamic
light scattering (DLS) have been used to provide quanti-
tative data for EVs (1417). Finally, the detection of
various protein markers commonly found in EVs (18) can
be carried out to further demonstrate the type of vesicles
isolated (9).
Body fluids
Methods used for the collection of body fluids and storage
procedures may largely influence the range of EVs iso-
lated from these fluids [see (9) for a detailed description],
and thereby the RNA profile of the body fluid contained
EVs. The method of choice for EVs isolation from
different body fluids may depend not only on the type
of body fluid, but also on the volume available, and
parameters such as the viscosity of the fluid. As with the
isolation procedures for cell culture derived EVs, publica-
tions should include a clear explanation of the steps used
(e.g. centrifugation parameters) to obtain and character-
ize the EVs from body fluids. It is also recommended to
establish a working protocol for the isolation of EVs and
subsequently RNA before processing of precious samples.
Parameters such as the delay in processing samples,
storage temperatures, and the available volume of samples
all contribute to the yield of EVs from which RNA is
extracted. Confirmation of the presence of EVs in the
sample, using the methods described above for cell culture
supernatants, is also necessary.
While sample collection procedures can be stan-
dardized to a certain degree, there will also be inherent
variablities in the samples that are more pronounced than
when using cell supernatants, which can be controlled
more readily. Proposed checklists for sample choice and
sample collection/processing are presented in detail in
Witwer et al. (9).
Treatment of samples with nuclease  or not?
Besides RNA associated to EVs, biological samples also
contain RNA species that may be bound to other
molecules such as proteins and lipid complexes (1921).
EvRNA should be protected from nucleases activity in
the environment by the EV lipid bilayer. RNase treatment
of EVs has therefore been used to discriminate evRNA
species from extracellular RNA not associated to EVs.
However, it should be noted that several body fluids
(e.g. saliva milk and urine) contain (high levels of)
nucleases, making the presence of RNase-sensitive com-
plexed RNAs in such fluids unlikely (22). Additionally,
proteins on the surface of EVs may bind and protect
Andrew F. Hill et al.
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RNA from degradation, hence the addition of exogenous
RNase tends to be ineffective in the absence of proteases.
It is currently unknown whether both nucleoprotein
complexes on the outside of EVs and luminal evRNA
can be functionally delivered to target cells. Nevertheless,
RNase treatment could be effective in removing contam-
inating RNA molecules passively released by dead cells
that may non-specifically stick to EVs in environments
that are low in nuclease content. Importantly, nuclease
levels in body fluids can change due to pathological
conditions. In cancer patients, for example, increased
levels of serum nucleases have been observed (23). Such
variations in nuclease levels should be taken into account
when analysing evRNA present in clinical samples.
Nevertheless, RNase treatment could be effective in
removing contaminating RNA molecules passively re-
leased by dead cells that may non-specifically stick to
EV’s in environments that are low in nuclease content.
The use of external spike-in RNA controls, to test
whether the EV-containing fluid being analysed contains
endogenous RNase activity, was discussed and consid-
ered to be unnecessary as the input material would be
degraded almost immediately, precluding downstream
detection (24).
RNaseA, which is specific for single-stranded RNA,
has been mostly used in evRNA analysis. A potential risk
in treating EV samples with RNase is that high concen-
trations of RNases are difficult to inhibit and residual
activity may affect the yields of RNA isolated from the
sample. The extent to which lysis buffers, used in the first
step of the evRNA isolation procedure, can control such
activity is unknown. In case RNase treatment of EVs is
applied, the effectiveness of the RNase treatment should
be assessed by combined treatment with detergents,
which should lead to more efficient and complete
degradation of the evRNA. Whether to treat a particular
sample with RNase or not depends on the research
question being asked. For instance, if the purpose of the
experiment is to examine how RNAs are selectively
incorporated into EV biogenesis, treatment with RNase
may be essential.
Besides the presence of extracellular RNA, some bio-
logical fluids are rich in DNA (for instance, plasma).
It should be noted that none of the available RNA
extraction methods excludes co-isolation of DNA en-
tirely, and that contaminating DNA may interfere in
RNA Bioanalyzer profiling and deep sequencing. It is
therefore advisable to treat samples suspected of DNA
contamination with DNase prior to evRNA isolation.
Considerations of the number of replicates
Another consideration when performing RNA deep
sequencing experiments is the number of replicates, which
can be either technical or biological in nature. The first
step of deep sequencing protocols is preparing the library
to be sequenced. In this step of the procedure some
variation may be introduced, depending on the protocol
and platform. The protocols for addition of adapters
as part of the library preparation vary between the
sequencing platform employed; the adapter sequences
vary widely and may introduce bias, which needs to be
assessed (see paragraph on library preparation). The use
of a second method for RNA detection is employed to
preferably validate the sequencing results (see below for
more details). The sequencing of the libraries on the
other hand seems highly reproducible. Repeated sequen-
cing of the same library is therefore not required, unless
for increasing the depth of sequence coverage. Increasing
the depth of sequence coverage not only allows for the
detection of rare transcripts, it may also identify
sequences of other origins such as those from bacterial
and viral sources. In addition to the sources of technical
variability listed above (i.e. library preparation and
sequencing), biological variability must also be estimated
and taken into account in order to detect significant
differences in RNA abundance. For this reason, including
biological replicates in the experimental design is critical
in order to obtain biologically meaningful results (25,26).
In the event that deep sequencing of evRNA in patient
samples is used for diagnostics, emphasis should be put
on defining biofluid-specific normatives and appropriate
control groups (9). Although small RNA sequences are
thought to have low genetic variability (27), the extent to
which small RNA expression levels vary between indivi-
duals has not been fully clarified. The choice to either
pool patient samples or perform RNA sequencing on
individual samples will also be dependent on the obtain-
able amount of RNA and financial resources.
Microarray analysis of RNA from EVs
While the discussion at the roundtable mainly focussed
on the use of deep sequencing approaches for the analysis
of EV RNA, microarray technology has also been used
to study this RNA. Microarrays are a well-established
technique for profiling the expression of known frag-
ments of nucleic acids using slide or chip-based media.
Microarrays are available for screening mRNA, miRNA,
long non-coding RNA (lncRNA) species and offer an
attractive advantage in that they do not rely on the use
of specialized sequencing equipment and/or complex
bioinformatics approaches (discussed below). However,
as microarrays use only known sequences as targets, the
ability to detect potentially novel sequences is therefore
not possible. Moreover, microarrays entail a risk for
probe cross-hybridization and, in contrast to NGS,
do not directly count the number of transcripts (28).
Also, given the updates to databases such as miRBase
(currently at version 20), microarrays need to be updated
in line with these. Nevertheless, microarrays present a
useful tool for profiling EV RNA species and have been
EV RNA analysis and bioinformatics
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used in studies of both EVs from cell culture systems and
those isolated from bodily fluids (16,29,30).
Deep sequencing platforms
Over the last couple of years, several technologies have
been developed for deep sequencing. Many rely on pro-
prietary kits and equipment for performing deep sequen-
cing. Presently, the major systems in use are the Illumina
HiSeq, Roche 454 pyrosequencing, and the SOLiD
system from Applied Biosystems. These platforms are
generally used in high-coverage sequencing projects and
operated through service providers. Recently, smaller
deep sequencing platforms have become available, which
allow individual laboratories to perform their own
sequencing. These include the MiSeq (Illumina), Ion
Torrent Personal Genome Machine (Life Technologies),
and the GS Junior (Roche). One consideration when
choosing a sequencing platform to use, or decide between
the personal or larger machines, is the depth of coverage
obtained with the particular system. Deeper coverage will
allow the analysis of rare sequences and give more
confidence in the number of reads per transcript. How-
ever, there are cost and time constraints, which also have
to be considered.
Library preparations from evRNA samples
Although the majority of RNA in various types of EVs
consists of small RNAs (20200 nt) (1,3,4,31,32), EVs
can also contain larger RNAs, such as mRNAs and low
levels of 18/28S ribosomal RNA (1,33). Sequencing of
small and large RNAs requires different steps in the
sequencing library preparation protocol. A comparison
of commonly used library preparation methods is given
in Table I. Since the small RNA pool in EVs can contain
small transcripts or cleavage products overlapping with
larger (non)coding RNAs, fragmentation of total RNA
isolates before library preparation can lead to erroneous
interpretation of the small evRNA profile. In general,
procedures should be carefully considered to ensure valid
interpretation and comparative analysis of sequencing
data. We have listed important points of consideration in
Table II.
Prior to library preparation, the evRNA size distribu-
tion should be analysed, e.g. by Bioanalyzer profiling,
and these data should be included in publications. It
should be noted that RNA Integrity Numbers (RIN),
provided by the Bioanalyzer software, are not indicative
of the integrity of small evRNA, since RIN are based on
the major 18S and 28S ribosomal RNA peaks that are
abundantly present in cells but not in most EV types.
Small RNAs can have different modifications at the
5?- and 3?-termini due to their diverse origins and bio-
genesis pathways. Some of these modifications are either
not reactive or less reactive to enzymatic manipulations
in the expression profiling protocols, such as adapter T
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ligation by T4 RNA ligase (35). Treatments of the RNA
pool to be sequenced with enzymes such as phosphatases
can be applied to enrich for or exclude classes of RNAs
in sequencing libraries (35).
The most widely used library construction methods
are listed in Table I. The library preparation generally
involves adapter ligation to both ends of the RNAs,
reverse transcription into cDNA and further amplifica-
tion using primers specifically annealing to the adapter
regions. It should be noted that biases might be introduced
during library preparation that can affect the quantitative
aspect of the expression profiling. These biases include
differences in the efficiency of adapter ligation to certain
RNAs due to the T4 ligase or differences in the barcode
sequences (in case of multiplex sequencing) and biases
introduced during polymerase chain reaction (PCR) am-
plification. Validation experiments using different techni-
ques can be used to confirm relative expression differences
between samples (see below).
The adapter-ligated cDNA can be run on a gel, after
which bands can be excised to exclude adapters without
inserts or to select for cDNAs in the preferred size range.
Images of the selected bands (with sizes) should be
supplemented in the publication, and it is advisable to
include a Bioanalyzer profile of the library. This latter
step, however, can cause substantial variation between
experiments. Although size selection may improve the
sequencing of specific products, the depth of sequencing
that can currently be achieved by the advanced deep
sequencing techniques is usually sufficient to be able to
detect rare products.
With regard to data comparability, the use of identical
protocols for library preparation is crucial for valid
and reproducible comparison of RNA levels between
different libraries. Nevertheless, external spike-in RNA
controls can be useful to evaluate the sensitivity, accu-
racy, and comparability of RNA-sequencing experiments
(39).
Bioinformatics and databases
Deep sequencing of evRNA generates massive amounts
of data, which need to be analysed using appropriate
bioinformatics tools. Quality metrics of the sequenced
reads  such as per-cycle quality score, nucleotide fre-
quency, and read complexity  give an important initial
estimate of the quality of the data. The alignment of
sequence data back to reference genome is a critical step
in the bioinformatic analysis of deep sequencing data.
Low-percentage alignment of sequencing reads against
the reference may indicate low quality or abundance
from the starting material. It is important to include
the alignment parameters (e.g. % alignment, database/
reference genome to which the data were aligned to) in
publications containing the RNA-sequencing data. Care
should also be taken when choosing what method to use
to normalize the data. Common normalization strategies
are based on the total number of mapped reads, the total
number of reads mapping to the features of interest (e.g.
total number of reads mapping to miRNAs), or spike-ins.
Since a standard consensus strategy is still lacking in the
field, ideally more than a single normalization methods
should be adopted to show the consistency of the results.
Among a number of possible approaches, the two most
likely strategies that emerged were to normalize over
either the total number of mapped reads or the number of
reads mapping to miRNAs. Each of the two approaches
has its advantages, and the choice depends on what
comparison one is trying to make.
Table II. Parameters with regard to sRNA library preparation that should be considered
Parameter Effects to be considered Approaches
RNA structures 1. Some 5?- or 3?-end modifications of RNA sequences
are not reactive or have reduced reactivity for
enzymatic steps (adapter ligations) involved in library
preparation.
2. Sequences of small RNAs and their secondary and
tertiary self-structures can affect the efficiency
of 3?- and 5?-adapter ligation (34).
Enzymatic treatments can be used to convert small
RNAs of interest to have appropriate and
homogenous ends in order to be ligated to adapters
with good efficiency (35).
RNA size distribution Potential transcript length bias Selection of small RNAs of specific sizes increases
sequencing depth for sequences of interest.
Library construction
method
1. Different barcode sequences can influence the
RNA and adapter cofold structures, which may
cause changes in ligation efficiency (36)
2. Occurrence of adapter dimers
Use barcodes positioned in primers during library
pre-amplification (37) or post-amplification barcode
strategies (38).
Removal of adapter dimers improves sequencing of
specific products; removal of non-productive
sequencing reads.
EV RNA analysis and bioinformatics
Citation: Journal of Extracellular Vesicles 2013, 2: 22859 - http://dx.doi.org/10.3402/jev.v2i0.22859 5
(page number not for citation purpose)
Furthermore, details as to the pipeline of data analysis
steps from sequencing to compiling the final results are
required. As many steps as is practicable should be
described in the publication, so that other researchers can
perform similar analysis using deep sequencing data from
other EV samples. This metadata will allow the analysis
of variability due to experimental conditions and proces-
sing parameters across different studies. This should in-
clude the processing steps applied to the raw data, any
details of trimming/clipping applied to the reads, criteria
for cut-off values, the databases used in the analysis, and
the order in which these steps were performed on the
data. The version numbers of any bioinformatics tools or
databases interrogated also need to be provided as these
are constantly being developed and updated.
As the field evolves to include sequence data from EVs
of different sources, the sharing of data is essential; both
as a reference tool and also with confirming previously
deposited data. It is important to deposit data sets
in relevant depositories including NCBI, and also in
EV-specific databases, including Vesiclepedia (40) and
EVpedia (41). The parameters described above should
also be deposited with the sequencing data.
Validation of deep sequencing data
Validating deep sequencing data arising from EV samples
with a different technique is important for a number of
reasons. Firstly, the preparation of sequencing libraries
and platforms differs between providers. Secondly,
validating data sets is important for standardization be-
tween different laboratories. The most commonly em-
ployed validation technique is quantitative real-time PCR
(qPCR). Validation with qPCR also allows the screening
of more biological replicates without the need for deep
sequencing of many samples. The choice of a normal-
ization control is important when comparing expression
levels between replicates and treatment conditions. It
should be noted that those household genes that are
generally used to normalize expression levels between
samples of cellular RNA are not per se appropriate
normalization controls in samples of evRNA. The relia-
bility of applied evRNA normalization controls should be
indisputably demonstrated by showing proof that incor-
poration levels of such control RNAs into EVs are steady
in each of the experimental conditions tested. In fact,
where possible, it is advisable to use multiple reference
genes for qPCR data normalization. A far more feasible
approach is to perform a global normalization to quan-
titative data, in which mean expression values of all
expressed small RNAs are used for data normalization
(42). Using this method, the ratio of two particular
miRNAs in the deep sequencing data could, for example,
be compared to the detected ratio using qPCR. The
advent of digital PCR techniques with which the exact
number of target molecules in a sample can be assessed
may assist in finding appropriate normalization controls
for each experiment.
Conclusions and perspectives
In-depth analysis of evRNA using advanced sequencing
techniques can yield valuable information on how geneti-
cally encoded messages are exchanged between cells.
However, methods that can be used for EV isolation,
evRNA isolation, sequencing library preparation, as well
as sequencing data analysis are highly diverse. To ensure
Table III. Checklist experimental details for publication
Step Parameters to be described
Cell culture Cell type
Confluency
Use of vesicle-depleted serum or serum-free
medium
Cell viability
Mycoplasma test
EV isolation Differential centrifugation steps
Filtration steps
Density gradient
Commercially available kits
(e.g. chemical, column based)
evRNA sample
preparation
RNase/DNase treatment of EVs
Use of RNA spike
RNA isolation method/kit
Bioanalyzer profile of evRNA
Library preparation Enzymatic treatment to remove phosphates,
caps, etc.
Method/kit for ligating adapters
Pre-amplification steps
Size selection steps
Bioanalyzer profile of library
Sequencing Platform
Maximum read length
Direction (paired or single end)
Number of cycles
Number of replicates (biological or technical)
Bioinformatics Pre-processing software (trimming/clipping,
cut-off values)
Reference genome assemblies (release
numbers)
Primary analysis software (alignment and
mapping criteria)
Browsers and annotation tools
Normalization methods and software
Statistical methods and tools for differential
expression analysis
Validation Validation technique
Normalization procedure
Deposition in
database
Name of database
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well-considered experimental setups and to allow for
inter-laboratory comparisons, it is important to com-
prehend parameters that can influence experimental
outcomes and include highly detailed descriptions of
experimental layouts in scientific publications. This also
allows for the sharing of knowledge that is often not in the
public domain, but which allows the evRNA field to move
forward more rapidly. Our current position statement is
based on the roundtable discussion on ‘‘evRNA analysis
and bioinformatics’’ during the ISEV workshop on RNA
in EVs, and provides points of consideration in setting up
evRNA sequencing analysis. In addition, we recommend
the specification of as many details as practicable in
publications containing such analysis. A checklist for
these details is provided in Table III. It is important to
provide all details on the RNA isolation and purification
methods used and RNA quality control experiments
performed. For the deep sequencing, the library prepara-
tion conditions need to be specified in terms of the
quantity of input RNA, kit used (including the version, as
these kits are continuously under improvement), and
quality control of the library itself. Furthermore, it is
important to report the sequencing conditions and to
provide quality scores (Q scores), depth of coverage, and
number of reads. Also with regard to the bioinformatics
analysis of the sequencing data, full details on processing
steps, criteria, and databases used should be reported.
Posting the raw data to one of the major databases
[e.g. Sequence Read Archive (SRA), Gene Expression
Omnibus (GEO), Vesiclepedia (www.microvesicles.org)
and EVpedia (www.evpedia.info)] is also essential, and
often a requirement of publishing, so that other research-
ers can assess the data. In conclusion, the points of
awareness and consideration raised in this paper should
help researchers in the field of evRNA to critically design
and control their experiments and should facilitate inter-
laboratory comparison of evRNA data sets.
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